Based on our bioinformatics analysis of the BRAF/MEK/PI3K oncogenic signature and numerous lines of evidence that mono-targeted therapies often fail to improve the outcome of cancer patients, including CRC, due to the development of drug resistance [59]. This evidence concerns the gene BRAF and colorectal carcinoma.